Is PETMR more accurate than PETCT imaging in the staging and management of gynaecological cancers?

Author(s): Erin Whiffing, Hollie Hadwen

Hospital: Alliance Medical, University of Suffolk

Reference: RAD Magazine, 46, 539, 15-16


Gynaecological cancers, those originating in the cervix, uterus, ovary, vulva and vagina, account for approximately one-quarter of all malignant disease in women. According to Cancer Research UK, approximately 21,760 new gynaecological cancers were diagnosed in 2016. Effective treatment planning is reliant upon precise and accurate staging.

PETCT is used in the staging and management of gynaecological cancers. CT offers anatomical detail, while PET, using 18F-fluorodeoxyglucose (FDG), demonstrates cells exhibiting a higher rate of glucose metabolism, a property common to many cancers. While PETCT plays a valuable role, the combined ionising radiation dose and soft tissue contrast may limit the staging of gynaecological malignancies. Pelvic assessment may be restricted by the spatial resolution of CT, hindering differentiation between normal soft tissue and abnormal malignant lesions.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more